Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Following a major outbreak involving the use of tear drops in 13 US states, experts are offering advice on how to protect dry eyes.
Read Full NewsPain that interferes with daily functioning is associated with higher odds of frailty and its progression in adult survivors of childhood cancer.
Cancer care is becoming too complex for any one clinician to track alone, making AI an increasingly valuable tool in modern oncology.
New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.
The CAPItello-281 trial reported a 19% improvement in radiographic progression-free survival.
1.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
2.
Study Supports More Inclusive Clinical Trials With Broader Eligibility Criteria
3.
Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC
4.
NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.
5.
US Counties Suffered Significantly from a Lack of Psychiatric Care.
1.
The latest research on Thyroid Cancer: Symptoms, Diagnosis, and Treatment Options
2.
Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation
3.
Mapping Gene Expression in Tumors: The Emerging Role of Spatial Transcriptomics
4.
The Dark Side of Melanoma: Uncovering the Risk Factors and Prevention Strategies
5.
Exploring the Causes and Treatment of Granulocytopenia: A Comprehensive Guide
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
3.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
4.
Thromboprophylaxis In Medical Settings
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge